Key result
Low-dose acetylsalicylic acid use was associated with a 4% reduced hazard for all-cause dementia overall (HR 0.96), with a stronger 34% reduction observed in patients with coronary heart disease.
Why the study?
No population-based cohort study had investigated a potential inverse association between long-term low-dose ASA use and all-cause dementia, Alzheimer disease, and vascular dementia.
Does low-dose acetylsalicylic acid reduce the incidence of all-cause dementia, Alzheimer's disease, and vascular dementia in community-dwelling older adults?
Population
Community-dwelling adults aged 55 or older from the ESTHER study (N = 5258) and UK Biobank (N = 305,394)
Comparison
Low-dose ASA use vs non-use
Design
Individual participant data meta-analysis of two prospective cohort studies
Follow-up
Median 14.3 years in ESTHER and 11.6 years in UK Biobank
Authors
Loading...
Should not yet change dementia prevention practice; leaves open a possible benefit of low-dose acetylsalicylic acid in coronary heart disease.
Meta-Analysis (n=310,652)
Yes
Does low-dose acetylsalicylic acid reduce the incidence of all-cause dementia, Alzheimer's disease, and vascular dementia in community-dwelling older adults?
Effect estimate: HR 0.96 (95% CI 0.93 to 0.99)
Long-term low-dose acetylsalicylic acid use is associated with a significantly reduced risk of all-cause dementia, Alzheimer's disease, and vascular dementia specifically in patients with pre-existing coronary heart disease.
Nguyen et al. (2022) conducted a meta-analysis in Dementia (n=310,652). Low-dose acetylsalicylic acid (ASA) vs. Non-users of low-dose ASA was evaluated on All-cause dementia incidence (HR 0.96, 95% CI 0.93 to 0.99). Low-dose acetylsalicylic acid use was associated with a 4% reduced hazard for all-cause dementia overall (HR 0.96), with a stronger 34% reduction observed in patients with coronary heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: